中国医院用药评价与分析Issue(10):890-892,893,4.DOI:10.14009/j.issn.1672-2124.2014.10.011
奥扎格雷钠联合灯盏花素治疗急性脑梗死的系统评价
Efficacy and Safety of Ozagrel Sodium Combined with Breviscapinun in the Treatment of Acute Cerebral Infarction:A Systematic Review
范燕 1许静 1孙晓1
作者信息
- 1. 江苏省连云港市第一人民医院药学部,江苏连云港 222002
- 折叠
摘要
Abstract
OBJECTIVE:To systematically evaluate the efficacy and safety of Ozagrel Sodium combined with Breviscapinun in the treatment of acute cerebral infarction ( ACI ) . METHODS: The randomized controlled trials ( RCTs) about Ozagrel Sodium plus Breviscapinun in the treatment of acute cerebral infarction were retrieved from Cochrane library, PubMed, EMbase, Wanfang Data, CNKI and VIP databases, meanwhile other relative literature was retrieved manually. Quality assessment about the methodology of the included studies was performed and meta-analysis of included studies was performed using Review Manager 5�2 software. RESULTS: Seventeen randomized controlled trials involving 1 641 patients were included. The meta-analysis showed the combined value of odds ratio( OR) was 3�90(95%CI=2�87-5�31)for the clinical efficacy of Ozagrel Sodium combined with Breviscapinun in the treatment of neurologic impairment in patients with acute cerebral infarction( ACI) and the combined value of the weighted mean difference( WMD ) was -4�20 ( 95%CI = -5�21--3�19 ) . CONCLUSIONS: Ozagrel Sodium plus Breviscapinun showed remarkable clinical efficacy and good safety for ACI. Due to the inferior quality of the included studies, more multi-center RCTs of high quality are needed to support this conclusion.关键词
奥扎格雷钠/灯盏花素/急性脑梗死/Meta分析Key words
Ozagrel sodium/Breviscapinun/Acute cerebral infarction/Meta-analysis分类
医药卫生引用本文复制引用
范燕,许静,孙晓..奥扎格雷钠联合灯盏花素治疗急性脑梗死的系统评价[J].中国医院用药评价与分析,2014,(10):890-892,893,4.